📊 RZLT Key Takeaways
Is Rezolute, Inc. (RZLT) a Good Investment?
Pre-revenue or minimal-revenue pharmaceutical company burning $51.6M in free cash flow with only $11.2M in cash reserves, indicating critical near-term solvency risk and urgent need for capital injection or revenue generation within 2-3 months to continue operations.
Rezolute, Inc. Key Strengths (RZLT)
- Low debt-to-equity ratio of 0.12x demonstrates conservative capital structure and minimal financial leverage
- Strong current ratio of 15.84x indicates adequate working capital relative to current liabilities
- Positive stockholders' equity of $116.8M provides residual asset base and equity cushion
RZLT Stock Risks: Rezolute, Inc. Investment Risks
- Catastrophic cash burn of -$51.6M FCF per period against only $11.2M cash reserves; ~2-3 month operational runway at current burn rate
- Absent or immaterial revenue (N/A reported) combined with -$57.1M net loss indicating pre-commercial or failed development stage
- Deeply negative profitability metrics: -48.9% ROE, -45.5% ROA, and -163.7x interest coverage signal fundamental business failure
Key Metrics to Watch
- Monthly cash burn rate and remaining cash runway to insolvency
- Evidence of revenue generation or approved commercial products
- Announcement of capital raise, financing facility, or strategic acquisition
Rezolute, Inc. (RZLT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 15.84x current ratio provides a solid financial cushion.
RZLT Profit Margin, ROE & Profitability Analysis
RZLT vs Healthcare Sector: How Rezolute, Inc. Compares
How Rezolute, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Rezolute, Inc. Stock Overvalued? RZLT Valuation Analysis 2026
Based on fundamental analysis, Rezolute, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Rezolute, Inc. Balance Sheet: RZLT Debt, Cash & Liquidity
RZLT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Rezolute, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.33 indicates the company is currently unprofitable.
RZLT Revenue Growth, EPS Growth & YoY Performance
Rezolute, Inc. Dividends, Buybacks & Capital Allocation
RZLT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Rezolute, Inc. (CIK: 0001509261)
📋 Recent SEC Filings
❓ Frequently Asked Questions about RZLT
What is the AI rating for RZLT?
Rezolute, Inc. (RZLT) has an AI grade of D with 88% confidence, based on fundamental analysis of SEC EDGAR filings.
What are RZLT's key strengths?
Claude: Low debt-to-equity ratio of 0.12x demonstrates conservative capital structure and minimal financial leverage. Strong current ratio of 15.84x indicates adequate working capital relative to current liabilities.
What are the risks of investing in RZLT?
Claude: Catastrophic cash burn of -$51.6M FCF per period against only $11.2M cash reserves; ~2-3 month operational runway at current burn rate. Absent or immaterial revenue (N/A reported) combined with -$57.1M net loss indicating pre-commercial or failed development stage.
What is RZLT's revenue and growth?
Rezolute, Inc. reported revenue of N/A.
Does RZLT pay dividends?
Rezolute, Inc. does not currently pay dividends.
Where can I find RZLT SEC filings?
Official SEC filings for Rezolute, Inc. (CIK: 0001509261) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is RZLT's EPS?
Rezolute, Inc. has a diluted EPS of $-0.55.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is RZLT's fundamental grade?
Based on our AI fundamental analysis in May 2026, Rezolute, Inc. has a D grade with 88% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is RZLT stock overvalued or undervalued?
Valuation metrics for RZLT: ROE of -48.9% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is RZLT's AI grade for 2026?
Our dual AI analysis gives Rezolute, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is RZLT's free cash flow?
Rezolute, Inc.'s operating cash flow is $-51.5M, with capital expenditures of $153.0K.
How does RZLT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -48.9% (avg: 15%), current ratio 15.84 (avg: 2).